PHILOGEN SPA (PHIL.MI) Stock Price, Forecast & Analysis
Europe - BIT:PHIL - IT0005373789 - Common Stock
PHIL.MI Key Statistics, Chart & Performance
The current stock price of PHIL.MI is 23.7 EUR. In the past month the price increased by 3.49%. In the past year, price increased by 18.5%.
PHIL.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.93 | 44.96B | ||
| 1AE.DE | ARGENX SE | 67.91 | 44.95B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.96B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.90B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 5CV.DE | CUREVAC NV | 5.17 | 1.01B | ||
| NANO.PA | NANOBIOTIX | N/A | 820.63M | ||
| IVA.PA | INVENTIVA SA | N/A | 517.80M | ||
| FYB.DE | FORMYCON AG | N/A | 341.03M | ||
| VLA.PA | VALNEVA SE | N/A | 314.28M | ||
| AYJ.DE | VALNEVA SE | N/A | 312.22M |
Related stock screener links
About PHIL.MI
Company Profile
Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 193 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company focuses mainly on discovering and developing targeted anti-cancer drugs, using high-affinity ligands for tumor markers. These ligands are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The Company’s products primarily address applications in the oncology field, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. The company has four anti-cancer antibody derivatives in clinical studies, one of which has completed a Phase III trial. The firm is active in the Discovery Unit through its subsidiary Philochem AG.
Company Info
PHILOGEN SPA
Via Bellaria, 35
Sovicille SIENA IT
Employees: 183
Phone: 39057717816
PHILOGEN SPA / PHIL.MI FAQ
What does PHILOGEN SPA do?
Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 193 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company focuses mainly on discovering and developing targeted anti-cancer drugs, using high-affinity ligands for tumor markers. These ligands are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The Company’s products primarily address applications in the oncology field, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. The company has four anti-cancer antibody derivatives in clinical studies, one of which has completed a Phase III trial. The firm is active in the Discovery Unit through its subsidiary Philochem AG.
What is the stock price of PHILOGEN SPA today?
The current stock price of PHIL.MI is 23.7 EUR. The price decreased by -2.07% in the last trading session.
What is the dividend status of PHILOGEN SPA?
PHIL.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHIL stock?
PHIL.MI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists PHIL stock?
PHIL.MI stock is listed on the Euronext Milan exchange.
Can you provide the growth outlook for PHILOGEN SPA?
The Revenue of PHILOGEN SPA (PHIL.MI) is expected to grow by 112.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does PHILOGEN SPA have?
PHILOGEN SPA (PHIL.MI) currently has 183 employees.
PHIL.MI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PHIL.MI. When comparing the yearly performance of all stocks, PHIL.MI turns out to be only a medium performer in the overall market: it outperformed 68.28% of all stocks.
PHIL.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PHIL.MI. PHIL.MI is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
PHIL.MI Financial Highlights
Over the last trailing twelve months PHIL.MI reported a non-GAAP Earnings per Share(EPS) of 1.14. The EPS increased by 255.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 58.33% | ||
| ROA | 28.81% | ||
| ROE | 36.49% | ||
| Debt/Equity | 0.08 |
PHIL.MI Forecast & Estimates
8 analysts have analysed PHIL.MI and the average price target is 28.56 EUR. This implies a price increase of 20.51% is expected in the next year compared to the current price of 23.7.
For the next year, analysts expect an EPS growth of 14.99% and a revenue growth 112.03% for PHIL.MI